In contrast to conventional chemotherapy, @entity3003 is still dosed per unit of body surface area (BSA) in high-dose chemotherapy protocols in clinical practice. To individualise dosing, a population pharmacokinetic model for poor-risk germ cell @entity5 @entity1 receiving 1500 mg m(-2) @entity3003 was developed. The typical central volume of distribution (19.9 l) and typical clearance (110 ml min(-1)) corresponded approximately to the extracellular fluid space or glomerular filtration rate, respectively. The covariate analysis identified several @entity1 -specific factors. @entity3003 clearance was significantly related to @entity1011 clearance and body height, explaining 73% of the interindividual variability. Thus, an equation to predict individual clearance prior to treatment was developed (CL=0.41 x @entity1011 clearance+1.05 x body height-124.4). The relative frequency of developing @entity137 increased significantly with higher AUC values for different types of @entity137 . In addition, overall nonhaematological @entity137 correlated significantly with exposure of @entity3003 , leading to the assessment of a target AUC. Based on the prediction of individual clearance and the definition of a target AUC associated with moderate @entity137 , an individualised dosing equation is proposed. Retrospectively, the individualised dosing strategy would have led to a higher dose on average and a broader range to be administered, compared to empirical dosing per unit BSA in the high-dose setting.

Individualised dosing strategy for high-dose XXXX in @entity1 with @entity5 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin', 'carboplatin'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']
@entity3003 :: (MESH:D016190,Chemical) :: ['carboplatin']
